BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302252% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines POBEVCY (bevacizumab biosimilar by Year
POBEVCY (bevacizumab biosimilar — Bio-Thera In-Licensed) ($M) ($M)
BeOne Medicines POBEVCY (bevacizumab biosimilar: $47.4M in FY2025, down 11.4% from a year earlier.
Latest, FY2025
47.4
Period ended Dec 31, 2025
Change on a year earlier
-11.4%
53.5 in FY2024
History
6 years
Since FY2020
Sources
4
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-Q / 10-K Segment Disaggregation Note (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | POBEVCY (bevacizumab biosimilar — Bio-Thera In-Licensed) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 47.4 | -11.4% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 53.5 | -5.3% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 56.5 | +48.3% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 38.1 | +2,621.4% | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 1.40 | – | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 0 | – | Form 10-K (filed 2023-02-27) ↗ |
Cite this data
StockData. (2026). BeOne Medicines POBEVCY (bevacizumab biosimilar ($M), annual FY2020–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod-pobevcy
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.